Gastroenterology, the Second Affiliated Hospital of Soochow University.
Gastroenterology, the First Affiliated Hospital of Soochow University.
Rev Esp Enferm Dig. 2020 Dec;112(12):893-897. doi: 10.17235/reed.2020.6937/2020.
both percutaneous transhepatic cholangiography and drainage (PTCD) and endoscopic retrograde cholangiopancreatography (ERCP) with SEMS implantation have been used for unresectable hilar cholangiocarcinoma (HC) in the clinic for many years. However, which one is preferred is still unknown.
to study the effects of biliary drainage of self-expanding metal stents (SEMS) implantation under PTCD or ERCP to treat HC.
the clinical data of 82 patients with HC from January 2006 to January 2015 were recorded retrospectively. Patients were treated with biliary implantation of self-expanding metal stents (SEMS) under PTCD (PTCD group, 40 patients) or ERCP (ERCP group, 42 patients). Clinical data, including total bilirubin concentrations, complications and survival time were analyzed.
the remission of jaundice was similar in both groups (p > 0.05). The median survival time of the ERCP group and PTCD group were 237 d and 252 d respectively, with no significant differences (p > 0.05). The biliary infection rates under ERCP and PTCD procedure were 52.4 % and 20.0 % respectively, with a significant statistical difference (p < 0.05). For those HC patients of Bismuth III/IV, the infection rates under ERCP and PTCD procedure were 58.3 % and 14.3 %, respectively (p < 0.05).
both PTCD and ERCP with SEMS implantation were effective to prolong the survival time of HC patients. The biliary infection rates were higher in the ERCP group, especially for Bismuth III/IV HC patients.
经皮经肝胆管造影术(PTCD)和内镜逆行胰胆管造影术(ERCP)联合支架置入术已在临床上用于治疗不可切除的肝门部胆管癌(HC)多年。然而,哪种方法更优仍不清楚。
研究经皮经肝胆管造影术(PTCD)或内镜逆行胰胆管造影术(ERCP)下胆道自膨式金属支架(SEMS)置入术治疗 HC 的效果。
回顾性记录 2006 年 1 月至 2015 年 1 月 82 例 HC 患者的临床资料。患者均行胆道自膨式金属支架(SEMS)置入术治疗,其中经皮经肝胆管引流术(PTCD 组,40 例)和内镜逆行胰胆管造影术(ERCP 组,42 例)。分析两组患者的临床资料,包括总胆红素浓度、并发症及生存时间。
两组患者黄疸缓解情况相似(P>0.05)。ERCP 组和 PTCD 组的中位生存时间分别为 237 d 和 252 d,差异无统计学意义(P>0.05)。ERCP 和 PTCD 组的胆道感染率分别为 52.4%和 20.0%,差异有统计学意义(P<0.05)。对于 Bismuth Ⅲ/Ⅳ型 HC 患者,ERCP 和 PTCD 组的感染率分别为 58.3%和 14.3%,差异有统计学意义(P<0.05)。
PTCD 和 ERCP 联合 SEMS 置入术均可延长 HC 患者的生存时间。ERCP 组的胆道感染率较高,尤其是对于 Bismuth Ⅲ/Ⅳ型 HC 患者。